Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

Contributed by: Business Wire

Logo

Tags

Biotechnology

Manufacturing

Other Manufacturing

Health

Pharmaceutical

Teva Pharmaceutical Industries Ltd.

More Like This

Samsung Bioepis office in Songdo, Incheon, Republic of Korea

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results